The test order rate per 1,000 patient-days fell from 126.5 in the pre-intervention period to 90.6 in the intervention period, a 28% reduction.
Screening patients for Clostridioides difficile colonization was not useful for preventing C difficile infection, Dutch researchers report.
SER-109, an investigational microbiome therapeutic for treating recurrent Clostridioides difficile infection, was well tolerated and showed clinical benefit.
Approval of Rebyota, made by Ferring Pharmaceuticals, was based on findings from multiple randomized clinical trials.
"C diff is one of the CDC's top five urgent antibiotic resistance threats. But it's the only one that isn't nationally notifiable."
A third of US active-duty military service members who tested positive for COVID-19 reported new-onset or more difficulty with exercise and daily activities 1 month after diagnosis, but these symptoms diminished to pre-infection levels after 6 to 9 months, according to research presented at this week's Infectious Diseases Society of America (IDSA) ID Week in Washington, DC.
A report published yesterday in Clinical Infectious Diseases describes a new SARS-CoV-2 mutation that confers resistance to the COVID-19 antiviral drug remdesivir in two persistently infected kidney transplant recipients treated with immunosuppressive drugs.
Swiss biopharmaceutical company Ferring Pharmaceuticals announced yesterday that the Food and Drug Administration's (FDA's) Vaccine and Related Biologic Products Advisory Committee (VRBPAC) voted in favor of the company's investigational fecal microbiota transplant (FMT)-based therapy.
The prevalence of Clostridioides difficile infection (CDI) in the United States declined during the COVID-19 pandemic, but inpatient mortality and treatment costs were higher, according to a paper published yesterday in Open Forum Infectious Diseases.
Central line-associated bloodstream infections, ventilator-associated events, and C difficile infections all increased.
